Related Experiment Video

Updated: Apr 24, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K

Relapsed and refractory multiple myeloma: new therapeutic strategies

Silvia Gentili1, Sagar Lonial2

  • 1Department of Hematology, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Via Conca 71, Ancona 60126, Italy.

Hematology/Oncology Clinics of North America
|September 13, 2014
PubMed

Insights

New myeloma treatments are improving outcomes, especially for relapsed or high-risk patients. Combinations of novel agents show promise for better disease control and advancing towards a cure for multiple myeloma.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Therapeutics

Background:

  • Multiple myeloma treatment has evolved, altering the disease's natural progression.
  • Relapsed and refractory myeloma present ongoing therapeutic challenges.
  • Advances in understanding myeloma genetics inform risk stratification.

Purpose of the Study:

  • To review current and emerging treatment strategies for multiple myeloma.
  • To highlight the importance of risk-adapted therapy in myeloma management.
  • To discuss the potential of novel therapeutic combinations.

Main Methods:

  • Review of recent clinical trials and therapeutic advancements in multiple myeloma.
  • Analysis of treatment efficacy based on patient risk stratification (standard vs. high-risk).
  • Evaluation of second-generation and novel agents in refractory myeloma.

Main Results:

  • Doublet therapy shows benefit for standard-risk myeloma patients.
  • Combination therapies are crucial for managing aggressive or high-risk myeloma.
  • Second-generation agents demonstrate significant activity in refractory disease.

Conclusions:

  • New treatment options are transforming multiple myeloma care, including for relapsed cases.
  • Tailored combination therapies represent the future direction for myeloma treatment.
  • Further research into novel agents and combinations is essential for achieving a cure.
Keywords:
Complete remissionEmerging agentsImmunomodulatory drugsMultiple myelomaPrognostic factorsProteasome inhibitorsRelapsed/refractory

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

12.5K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K